ライフサイエンスコーパス: long-term survival

1 three oncological outcome domains (including long-term survival).

2 ansplantation may offer their best chance at long-term survival.

3 ing mutated IDH1, Bcl-xL inhibition leads to long-term survival.

4 imited by the lack of robust improvements in long-term survival.

5 nt for newly diagnosed MM is associated with long-term survival.

6 rations-differences that may be essential to long-term survival.

7 as associated with a significant increase in long-term survival.

8 off 1.6 g/L) were associated with short- and long-term survival.

9 tributing factors to the observed changes in long-term survival.

10 cm(-5) at reassessment correlated with worse long-term survival.

11 Abstinence is essential for long-term survival.

12 cepacia can make a significant difference in long-term survival.

13 ation between the route of the procedure and long-term survival.

14 nd the value of aortic valve (AV) surgery on long-term survival.

15 otentially reduce ICU admissions and improve long-term survival.

16 sociated with increased morbidity and poorer long-term survival.

17 5, their need for reinterventions, and their long-term survival.

18 of patients with cN+ bladder cancer achieves long-term survival.

19 molecules and subsequently displays enhanced long-term survival.

20 vide the needed substitute energy source for long-term survival.

21 nd these events pose the greatest threats to long-term survival.

22 seline RVSP is independently associated with long-term survival.

23 nfarction are associated with differences in long-term survival.

24 ugh surveillance is associated with improved long-term survival.

25 to assess the influence of PCI on short- and long-term survival.

26 the WGD and how this may be linked to their long-term survival.

27 abnormalities that are associated with poor long-term survival.

28 ed with higher operative mortality and lower long-term survival.

29 peutic agents and significant differences in long-term survival.

30 patients have ongoing morbidity and reduced long-term survival.

31 (iv) length of hospital stay (LOS), and (v) long-term survival.

32 tive recovery, and are associated with worse long-term survival.

33 erioperative risk factors and predictors for long-term survival.

34 ated in patients with CKD and portend poorer long-term survival.

35 reas few patients with advanced disease have long-term survival.

36 CC and recurrence, de novo cancer, and worse long-term survival.

37 and that AQP9 is vitally required for their long-term survival.

38 unadjusted rates of mortality and decreased long-term survival.

39 normal-weight central obesity had the worst long-term survival.

40 ial proportion of elderly patients will have long-term survival.

41 ikelihood of discharge to home, and improved long-term survival.

42 e metastases offers the only opportunity for long-term survival.

43 , dexrazoxane use did not seem to compromise long-term survival.

44 and the correlation between patient TILs and long-term survival.

45 for health behaviours, preventive care, and long-term survival.

46 better operative outcomes without impairing long-term survival.

47 d patients with advanced melanoma experience long-term survival.

48 sults in a good initial response but limited long-term survival.

49 ce after an episode of AH positively impacts long-term survival.

50 a, allowing some subsets of patients to have long-term survival.

51 F receptor and CD19/PI3K signaling for their long-term survival.

52 ant chemotherapy is associated with improved long-term survival.

53 d autologous stem cell rescue with improving long-term survival.

54 n trial is insightful as focus shifts toward long-term survival.

55 ws lower early complication rates and better long-term survival.

56 s) has improved the predictions of patients' long-term survival.

57 YC, MINA53, and Ki67 in predicting patient's long-term survival.

58 accompanied by biologic effects that reduced long-term survival.

59 py (BCT) and mastectomy result in equivalent long-term survival.

60 fibrillation, negatively affects short- and long-term survival.

61 A. terreus conidia remained persisting with long-term survival.

62 gh COX5B, low GLUT1) had improved short- and long-term survival.

63 ransplantation may offer a greater chance of long-term survival.

64 ntiated cancers with excellent prognosis and long-term survival.

65 nts with localized disease likely to achieve long-term survival.

66 ntly prevented relapse of PDAC, allowing for long-term survival.

67 th out-of-center cannulation showed improved long-term survival.

68 AR, respectively, there was no difference in long-term survival (5 years 60% versus 58%, P=0.771), in

69 No difference was found in long-term survival (adjusted hazards ratio [HR] 1.03; 95

70 Although the long-term survival advantage of multiple arterial grafti

71 ant predictor of perioperative mortality and long-term survival after AAA repair in propensity-matche

72 ght to determine sex and race differences in long-term survival after AMI using life expectancy and Y

73 the effect of postoperative complications on long-term survival after colorectal cancer (CRC) resecti

74 relationship between baseline serum TMAO and long-term survival after coronary angiography.

75 The impact of early morbidity on long-term survival after curative-intent CRC surgery rem

76 The impact of SEAL upon long-term survival after esophageal resection remains in

77 ulopathy (CAV) remains the Achilles' heel of long-term survival after heart transplantation.

78 on, which have been associated with improved long-term survival after HT.

79 , whereas CD8(+) T cells are dispensable for long-term survival after intracerebral challenge.

80 eport the effect of intravenous alteplase on long-term survival after ischaemic stroke of participant

81 and intense conventional immunosuppression, long-term survival after lung transplantation lags behin

82 Long-term survival after lung transplantation remains po

83 ysfunction (CLAD) is the major limitation of long-term survival after lung transplantation.

84 sfunction is a heterogeneous entity limiting long-term survival after lung transplantation.

85 and infarct size (ISZ) are key predictors of long-term survival after myocardial infarction (MI).

86 In the current era, with long-term survival after systemic treatment, there is a

87 nd growth monitoring, as well as to evaluate long-term survival after treatment.

88 ure and its standard deviation (SD) affected long-term survival among the 13 million Medicare benefic

89 We now report a long-term survival analysis of that trial.

90 mpact of complete abstinence from alcohol on long-term survival and (2) identify prognostic factors a

91 confers an energetic disadvantage to PCs for long-term survival and antibody production.

92 n of transcriptional mechanisms that support long-term survival and differentiation of repair cells w

93 However, a number of questions remain about long-term survival and evolution of V. cholerae strains

94 Ross procedure with the aim of defining very-long-term survival and factors associated with Ross-rela

95 Long-term survival and freedom from major cardiovascular

96 Long-term survival and freedom from reintervention were

97 protein-1 transcriptional nexus involved in long-term survival and function.

98 Predictions of long-term survival and functional outcomes influence dec

99 eviewed the literature for studies reporting long-term survival and ICH recurrence, and their predict

100 obacteria to cope with hypoxia, resulting in long-term survival and increased chemotherapeutic tolera

101 g retinal environment significantly improves long-term survival and integration of hESC-derived donor

102 vere esophageal anastomotic leak (SEAL) upon long-term survival and locoregional cancer recurrence.

103 ereby promoting tissue tolerance by limiting long-term survival and maintenance of CD4+ effector T ce

104 Our data confirm excellent long-term survival and maintenance of good functional st

105 cal prosthetic valves is challenging because long-term survival and morbidity are not well defined.

106 esion patterns significantly associated with long-term survival and neurologic outcome.

107 the transcriptional mechanisms that control long-term survival and phenotype of repair cells have no

108 ation between combined EA-GA vs GA alone and long-term survival and postoperative complications in pa

109 Long-term survival and predictors of long-term mortality

110 r hemodialysis patients because of increased long-term survival and preservation of quality of life.

111 peat revascularization and an improvement in long-term survival and should be considered more frequen

112 The standard of care to enhance long-term survival and stabilize cerebral disease is a h

113 Clinical benefit, including long-term survival and tumour regression, can still occu

114 iated with lower operative mortality, better long-term survival, and fewer valve-related complication

115 Operative outcomes, long-term survival, and functional outcomes were compare

116 mechanisms that suppress outgrowth, support long-term survival, and maintain tumor-initiating potent

117 ) scaffold niche for successful engraftment, long-term survival, and maturation of lung epithelium in

118 ansplantation led to high engraftment rates, long-term survival, and progressive maturation of human

119 Most patients have poor long-term survival, and treatment has not significantly

120 plementation are, how the QIs are related to long-term survival, and whether quality categorization i

121 m prognosis, whereas factors associated with long-term survival are largely unknown.

122 adiation, and traditional chemotherapy; with long-term survival as low as 50-60% for Sonic Hedgehog (

123 utcomes were 30-days all-cause mortality and long-term survival at end of the follow-up.

124 We investigated whether EVAR had a long-term survival benefit compared with open repair.

125 wo years of adjuvant tamoxifen resulted in a long-term survival benefit in premenopausal patients wit

126 rent study, we aimed to assess if there is a long-term survival benefit of BIMA up to 10 years after

127 es, surgical revascularization seems to have long-term survival benefit on the basis of observational

128 To demonstrate a long-term survival benefit with ipilimumab, we evaluated

129 RNA led to tumor regression, and substantial long-term survival benefit.

130 n IRD kidney was associated with substantial long-term survival benefit; providers should consider th

131 Given its association with long-term survival, better predictors of response and mo

132 a approximately 50% increase in SMN leads to long-term survival, but the SMA phenotype is only partia

133 her exploration of pathological outcomes and long-term survival by means of prospective randomized tr

134 meliorates acute toxicity, but also improves long-term survival by preventing lymphoma development.

135 leural (five of nine) and exhibited improved long-term survival compared to mesothelioma patients wit

136 effect of a liberal transfusion strategy on long-term survival compared with a restrictive transfusi

137 enefits in survival resulting in nearly 100% long term survival, confirmed by MRI and histological an

138 thers did not appear to suffer any short- or long-term survival costs from caring for cubs, but exten

139 Long-term survival data are lacking, and prognostic fact

140 Long-term survival data are lacking, and prognostic fact

141 ile denosumab was found to reduce fractures, long-term survival data are still required.

142 based on the ALBI grade offers personalized long-term survival data for patients with early-stage HC

143 n = 18,624), combined with baseline risk and long-term survival data from an external ACS patient coh

144 Long-term survival, defined as surviving at least 10 yea

145 s, but may increase the probability of their long-term survival during the co-evolution of hosts and

146 to be widely adopted because of the lack of long-term survival estimates of after C-stage incorporat

147 ved LVEF demonstrated significantly improved long-term survival following AV surgery.

148 ith double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse.

149 bypass surgery was associated with improved long-term survival for all patients undergoing surgery a

150 The association between prompt treatment and long-term survival for each rhythm type was assessed wit

151 have resulted in significant improvement in long-term survival for many types of cancer but have als

152 Long-term survival for patients treated with prolonged m

153 nterventional therapy, whereas improving the long-term survival for post-TIPS patients.

154 djusted analyses, there was no difference in long-term survival for right-sided compared with left-si

155 e hysterectomy does not appear to compromise long-term survival for women with endometrial cancer.

156 atment was not statistically associated with long-term survival (hazard ratio [HR] = 0.99, 95% confid

157 ported in 39% and was associated with better long-term survival (hazard ratio, 0.53; P = 0.03).

158 was independently associated with decreased long-term survival [hazard ratio, 1.24; 95% confidence i

159 Long-term survival, health-related quality of life, and

160 ity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+)

161 ll response results in tumor eradication and long-term survival in 60% of the animals (p < 0.001).

162 to 14 days after tumor implant, resulted in long-term survival in 60% to 90% of animals with no asso

163 Their impact on long-term survival in adult liver transplantation (LT) i

164 To assess long-term survival in adult patients with severe acute l

165 ponse in more than 80% of the patients and a long-term survival in at least 50% of the cases.

166 nd with significant toxicity is required for long-term survival in CLL.

167 with everolimus-eluting stent had comparable long-term survival in comparison with CABG.

168 in whether coeliac node metastasis precludes long-term survival in distal oesophageal cancer.

169 There was a trend toward long-term survival in favor of GemErlo (estimated surviv

170 e differential expression is associated with long-term survival in GBM patients.

171 h the impact of eye-preserving treatments on long-term survival in heritable retinoblastoma, and the

172 to the evidence supporting the durability of long-term survival in ipilimumab-treated patients with a

173 ndrome (RAS) is the major limiting factor of long-term survival in lung transplantation.

174 erapy at 1, 2, and 3 months led to drug-free long-term survival in maximally immunologically mismatch

175 to evaluate the impact of PCI on short- and long-term survival in out-of-hospital cardiac arrest pat

176 The outcomes were short-term and long-term survival in patients with shock-resistant vent

177 This study investigated long-term survival in patients with type 1 DM (T1DM) and

178 conclude that MDM2 maintains homeostasis and long-term survival in podocytes by preventing podoptosis

179 onary venous blood (IPVB) could predict poor long-term survival in resected non-small cell lung cance

180 We demonstrate that to permit long-term survival in response to sudden glucose depleti

181 We assessed short-term and long-term survival in severe alcoholic hepatitis based o

182 st that NIF is beneficial for short-term and long-term survival in shock-resistant ventricular fibril

183 of all types of eye-preserving therapies on long-term survival in the complete German cohort of pati

184 We evaluated the effect of CRT-D on long-term survival in the MADIT-CRT population.

185 analysis demonstrated significantly greater long-term survival in the postprotocol period (log-rank

186 c of their native site, thus promoting their long-term survival in their natal habitat.

187 is steadily increasing, but the knowledge on long-term survival in this group is scarce.

188 ch will in turn translate into remission and long-term survival in this patient population.

189 l discharge may be important determinants of long-term survival in veno-venous extracorporeal membran

190 y CD8(+) TRM cells and greatly reduces their long-term survival in vivo, while having no effect on th

191 r CRC resection is associated with decreased long-term survival, independent of patient, disease, and

192 erative risk and is associated with superior long-term survival, irrespective of sex and diabetic mel

193 tcomes to widely metastatic disease in which long-term survival is approximately 40% despite intensiv

194 ly with small cell lung cancer, although the long-term survival is hardly sustainable.

195 nitis and AIDS, if there is immune recovery, long-term survival is likely, whereas if there is no imm

196 re-resection for both patient selection and long-term survival is not known.

197 ion (S2P), a physician-modifiable factor, on long-term survival is not well understood.

198 Long-term survival is possible after resection of liver

199 Long-term survival is possible after resection of liver

200 Although PADC remains a deadly disease, long-term survival is possible, even beyond the 10-year

201 wing elderly population, and their effect on long-term survival is unknown.

202 ide population-based cohort study to analyze long-term survival, major adverse cardiovascular events,

203 (100 mum) or K25 at 2 days in vitro induced long term survival of CGNs in K5 conditions.

204 ) and Royal College of Pathologists (RCP) on long-term survival of 180 patients with resected pT3 tum

205 mes, decreased infection rate, and increased long-term survival of 2D2 and C57BL/6J wild-type mice.

206 V DNA rate of 100% at 8 years, and excellent long-term survival of 85% at 9 years.

207 er remodeling is a promising avenue to limit long-term survival of a majority of melanomas that harbo

208 regulating morphological differentiation and long-term survival of adult-born olfactory bulb neurons.

209 uppressor monocytes, have been implicated in long-term survival of allografts in both human transplan

210 erica, is caused by Borrelia burgdorferi The long-term survival of B. burgdorferi spirochetes in the

211 minated, while larger initial colonies allow long-term survival of both phage-resistant mutants and,

212 Here, we describe a reproducible, long-term survival of cardiac xenografts from alpha 1-3

213 We aimed to systematically analyse long-term survival of critically ill patients treated wi

214 In anoxic groundwater aquifers, the long-term survival of Dehalococcoides mccartyi populatio

215 inhibition is not sufficient to promote the long-term survival of ECM-detached cells.

216 of a caspase-independent cell death and the long-term survival of FA-treated cells.

217 ional deletion of HDAC11 within Tregs led to long-term survival of fully MHC-mismatched cardiac allog

218 ailed dendritic growth, spine formation, and long-term survival of GCs, pointing to the essential rol

219 cing the metabolic changes necessary for the long-term survival of Leishmania in a purine-scarce envi

220 pothesized effects on seed dispersal and the long-term survival of Malagasy plant lineages.

221 ts provide evidence supporting the idea that long-term survival of marine species in acidic condition

222 Long-term survival of pathogenic microorganisms in strea

223 We aimed to describe the short- and long-term survival of patients with CAUTI and the impact

224 We assessed the effects of MHE on the long-term survival of patients with cirrhosis.

225 Obective: To assess the long-term survival of patients with GIST who were treate

226 The long-term survival of patients with Mustard and Senning

227 The long-term survival of patients with severe defects impro

228 novel systemic treatments that can result in long-term survival of patients with widely metastatic me

229 present with reasonable visual function and long-term survival of photoreceptors layers.

230 (AML), little progress has been made in the long-term survival of relapsing AML patients, urging for

231 It supports the long-term survival of repair Schwann cells and is requir

232 erm neurotrophin treatment is sufficient for long-term survival of SGCs, and it can restore or preser

233 y graft loss of cell transplants and reduced long-term survival of solid organ transplants, we hypoth

234 vasculopathy (TAV) is the major obstacle for long-term survival of solid organ transplants.

235 ng B cells, also suggests B-cell-independent long-term survival of some PCs.

236 anules was correlated with a decrease in the long-term survival of stationary-phase cells.

237 uggesting a key role for inflammation in the long-term survival of target-deprived afferent neurons.

238 entrations, the mutualistic behavior enables long-term survival of the oscillating populations; howev

239 ce population of disease-free devils for the long-term survival of the species.

240 We examined the long-term survival of these children in Australia and Ne

241 of which remain obscure, markedly limits the long-term survival of these patients.

242 Ensuring the long-term survival of these species requires a well-deve

243 wth rate of the population decreases and the long-term survival of this turtle population is threaten

244 ver, the biological pathways that enable the long-term survival of TRM cells are obscure.

245 shown in different species to influence the (long-term) survival of novel genes.

246 95% confidence interval (CI): 0.91-1.71) or long-term survival (OR: 1.00, 95% CI: 0.63-1.57).

247 rm survival (OR: 0.85, 95% CI: 0.63-1.15) or long-term survival (OR: 1.25, 95% CI: 0.67-2.31) between

248 m survival (OR: 3.23, 95% CI: 2.21-4.72) and long-term survival (OR: 1.88, 95% CI: 1.36-2.59).

249 To investigate the effect of capecitabine on long-term survival outcomes of patients with early breas

250 riteria for Adverse Events, version 4.0, and long-term survival outcomes were reported and stratified

251 ng to nilotinib are associated with improved long-term survival outcomes, our results suggest that pa

252 illary and breast pCR after PST had superior long-term survival outcomes.

253 ft-bearing mice showed significantly greater long-term survival over beta-lap-dC6 micelles or beta-la

254 sease, and Fontan physiology had much poorer long-term survival (P<0.0001 for all).

255 Comparison of long-term survival probabilities under different treatme

256 No agreement has been reached on the long-term survival prospects for patients with Cushing's

257 therapies have limited effectiveness and the long-term survival rate is low.

258 Long-term survival rates for older patients with newly d

259 However, the long-term survival rates have remained very low.

260 st curable pediatric and adult cancers, with long-term survival rates now exceeding 90% after treatme

261 is for patients with localized osteosarcoma; long-term survival rates of less than 20% improved to 65

262 To compare long-term survival rates of patients with first, primary

263 Enhanced long-term survival rates of young women with cancer and

264 episode of mild AKI have significantly lower long-term survival rates than critically ill patients wi

265 an ablative dose of RT for large IHCCs, with long-term survival rates that compare favorably with res

266 crowns and fixed dental prostheses have high long-term survival rates when inserted with conventional

267 Early-stage diagnosis is important for long-term survival rates.

268 ent with advanced disease, resulting in poor long-term survival rates.

269 Endpoints were short- and long-term survival rates.

270 I/ARB after AMI was associated with improved long-term survival, regardless of underlying renal funct

271 We assessed perioperative and long-term survival, reinterventions, and complications a

272 reatments are only marginally effective, and long-term survival remains an unmet goal.

273 Long-term survival remains low for most patients with gl

274 tracorporeal membrane oxygenation treatment, long-term survival seems good, especially in patients tr

275 atients cured by pituitary surgery alone had long-term survival similar to that of the general popula

276 Assessment of transport stability, long-term survival, structural organization, functional

277 coronary artery bypass grafting have better long-term survival than those receiving a single interna

278 We conclude that transfusion may reduce long-term survival through its effects on perioperative

279 illation was associated with higher rates of long-term survival throughout 5 years of follow-up, wher

280 on for noninfectious indications had similar long-term survival to that for capping and abandoning le

281 ly a subgroup of patients responds and shows long-term survival to these therapies.

282 Finally, long-term survival was evaluated using the Kaplan-Meier

283 The overall long-term survival was excellent, with a 12-year surviva

284 Long-term survival was excellent.

285 ss, secondary patency was close to 100%, and long-term survival was good.

286 Long-term survival was higher after HLA-matched sibling

287 Unlike previous reports, long-term survival was lower in Ross patients compared w

288 Long-term survival was not significantly different in pa

289 Long-term survival was similar for patients regardless o

290 Long-term survival was worse and costs of care higher fo

291 sed risk of death within the first year, but long-term survival was worse for patients remaining on t

292 Clinicopathological factors and long-term survival were compared for 44 514 patients dia

293 nd rates of 90-day mortality, morbidity, and long-term survival were evaluated.

294 tive morbidity, use of adjuvant therapy, and long-term survival were examined after propensity score

295 tional hazard model, factors associated with long-term survival were initial shockable rhythm (hazard

296 Both clinical response and long-term survival were less favorable in patients under

297 However, the effect of EA on long-term survival when used as an adjunct to general an

298 ransplantation (LT) has shifted attention to long-term survival, where efforts are now needed to achi

299 density of TLS-associated DC correlated with long-term survival, which also allowed a distinction of

300 Though allogeneic transplantation results in long-term survival with acceptable social function, stra